Torrent Pharma announces fiscal 2025 Q2 results. In which the company's revenue increased by 9% to ₹ 2,889 crore. Gross margin 76.5%, Op. EBITDA margin 32.5%
Op. EBITDA increased by 14% to ₹939 crore. Net profit after tax increased by 17% to ₹ 453 crore. Insulin revenue was impacted in the quarter due to a scheduled shutdown in August for maintenance activities. The scheduled manufacturing shutdown will be lifted in December, so the shortfall is planned to recover significantly in the fourth quarter of this year, resulting in no impact on the performance of the full financial year. Adjusted for the above, revenue growth in the quarter is 10% with operating EBITDA growth at 16%.
India: Revenue in India grew 13% to ₹1,632 crore on outperformance in Focus Therapy According to AIOCD secondary market data, IPM growth for the quarter was 8%. Torrent's chronic business grew at 14% while IPM growth was 9%, the company's business growth attributed to strong improvements in cardiac segments and continued success in new anti-diabetes (OAD) launches. Based on MAT, Torrent outperformed the market across all focused therapies with strong performance from new launches. Among IPM's top 500 brands, 21 brands belong to torrent, of which 13 brands are worth more than 100 crores. The company's revenue for the first half of FY2025 was ₹3,267 crore, up 14%.
Brazil: Brazil revenue grew 4% to ₹263 crore Constant currency revenue increased 17% to R$ 174 million. As of IQVIA QTD August 24, torrent growth stood at 8% in the quarter, while market growth was 8%. Good performance of the company's top brands, new launches and growth in the generic segment enabled the company's revenue to grow. Application for approval of Torrent's new 21 products is currently pending with ANVISA. In the first half of FY2025, the company's revenue stood at ₹459 crore with an increase of 4%. (Constant currency revenue: increased by 13% to R$ 297 million)
Germany: Revenue in Germany grew by 8% to ₹288 crore Constant currency revenue was 31 million euros with an increase of 6%. For the last five quarters, the company has maintained its growth by continuously getting new tenders. In the first half of FY2025, the company's revenue stood at ₹572 crore with an increase of 9%. (Constant currency revenue: increased by 8% to 63 million euros)
Americas: The company's revenue in the Americas grew by 8% to ₹268 crore Constant currency revenue was $32 million, an increase of 7% compared to the previous quarter, with sales at the same level as the previous quarter. In the first half of FY2025, the company's revenue has declined by 3% to ₹527 crore. (Constant currency revenue: down 4% to $63 million) while revenue rose 2% compared to the first six months of fiscal 2023-24.
Image Credit: (Divya-Bhaskar): Images/graphics belong to (Divya-Bhaskar).
